Pliant Therapeutics, Inc.
PLRXNASDAQHealthcare● Active
$1.15
+$0.00(+0.00%)
Market Cap$71208230
P/E Ratio—
52W High$1.95
52W Low$1.09
Pliant Therapeutics, Inc. (PLRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PLRX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.32
Est. -$0.36 · +11.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
PLRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.33 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.36 | -$0.32 | +11.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 11, 2026 | -$0.42 | -$0.35 | +16.7% | — | $0.01B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.53 | -$0.43 | +18.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.62 | -$0.71 | -14.5% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.78 | -$0.92 | -17.9% | — | — | — |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.99 | -$0.82 | +17.2% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.99 | -$0.95 | +4.0% | — | $0.00B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.32
EPS Est.
-$0.36
EPS Surpr.
+11.1%
Revenue
—
Q1 FY2026
Mar 11, 2026Beat
EPS Actual
-$0.35
EPS Est.
-$0.42
EPS Surpr.
+16.7%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.43
EPS Est.
-$0.53
EPS Surpr.
+18.9%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.71
EPS Est.
-$0.62
EPS Surpr.
-14.5%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.92
EPS Est.
-$0.78
EPS Surpr.
-17.9%
Revenue
—
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.82
EPS Est.
-$0.99
EPS Surpr.
+17.2%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.95
EPS Est.
-$0.99
EPS Surpr.
+4.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q3 FY2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q2 FY2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q1 FY2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q4 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q3 FY2026 | $-0.41 | $-0.36 | $-0.33 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +11.1% | $1.22 | $1.20 | -1.64% |
| ▲ Q1 FY2026 | Mar 11, 2026 | +16.7% | $1.39 | $1.33 | -4.32% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +18.9% | $1.64 | $1.53 | -6.71% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -14.5% | $1.69 | $1.68 | -0.59% |
| ▼ Q2 FY2025 | May 8, 2025 | -17.9% | $1.43 | $1.46 | +2.10% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +17.2% | $3.44 | $1.38 | -59.88% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +4.0% | $15.70 | $15.19 | -3.25% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -8.2% | $13.11 | $12.54 | -4.35% |
Q2 FY2026-1.64%
Report Date
May 11, 2026
EPS Beat/Miss
+11.1%
Price Before
$1.22
Price After
$1.20
Q1 FY2026-4.32%
Report Date
Mar 11, 2026
EPS Beat/Miss
+16.7%
Price Before
$1.39
Price After
$1.33
Q4 FY2025-6.71%
Report Date
Nov 6, 2025
EPS Beat/Miss
+18.9%
Price Before
$1.64
Price After
$1.53
Q3 FY2025-0.59%
Report Date
Aug 7, 2025
EPS Beat/Miss
-14.5%
Price Before
$1.69
Price After
$1.68
Q2 FY2025+2.10%
Report Date
May 8, 2025
EPS Beat/Miss
-17.9%
Price Before
$1.43
Price After
$1.46
Q1 FY2025-59.88%
Report Date
Mar 3, 2025
EPS Beat/Miss
+17.2%
Price Before
$3.44
Price After
$1.38
Q4 FY2024-3.25%
Report Date
Nov 7, 2024
EPS Beat/Miss
+4.0%
Price Before
$15.70
Price After
$15.19
Q3 FY2024-4.35%
Report Date
Aug 7, 2024
EPS Beat/Miss
-8.2%
Price Before
$13.11
Price After
$12.54
Avg Beat Reaction-15.16%
Avg Miss Reaction-0.95%
Beat Rate5 / 8 quarters
Largest Move-59.88% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PLRX ends December
Pliant Therapeutics, Inc. (PLRX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.32 — beating the analyst consensus of $-0.36 by +11.1%. PLRX has beaten EPS estimates for 3 consecutive quarters. The next PLRX earnings date is expected around September 1, 2026.
Each quarter, investors track PLRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PLRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PLRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PLRX earnings · 5 questionsPliant Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. PLRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PLRX historically reports after market close (AMC).
PLRX earnings datewhen is PLRX earningsPLRX next earnings datewhen does PLRX report earningsPLRX earnings calendar
▸ Source: FMP · Pliant Therapeutics, Inc. SEC filings · US GAAP · Pliant Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026